Document ID: chunk:federal_register_of_legislation:F2022C00932:front:0:p3
Version: federal_register_of_legislation:F2022C00932
Segment Type: other
Provision Reference: 
Character Range: 5647–8645

least the five years before the clinical onset of anosmia;
            Note: perennial allergic rhinitis is defined in the Schedule 1 - Dictionary.
(3)          having an autoimmune disease from the specified list of autoimmune diseases at the time of the clinical onset of anosmia;
            Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(4)          having sarcoidosis at the time of the clinical onset of anosmia;
(5)          having Paget's disease of bone affecting the skull at the time of the clinical onset of anosmia;
(6)          having a neurological disease from the specified list of neurological diseases at the time of the clinical onset of anosmia;
            Note: specified list of neurological diseases is defined in the Schedule 1 - Dictionary.
(7)          having hepatic encephalopathy at the time of the clinical onset of anosmia;
(8)          having chronic renal failure at the time of the clinical onset of anosmia;
            Note: chronic renal failure is defined in the Schedule 1 - Dictionary.
(9)          having alcohol-induced major neurocognitive disorder, amnestic-confabulatory type, persistent or alcohol use disorder at the time of the clinical onset of anosmia;
(10)      having a condition or procedure from the specified list of conditions and procedures, which damages the olfactory neuroepithelium, the olfactory bulb or the olfactory neural pathways in the brain at the time of the clinical onset of anosmia;
            Note: specified list of conditions and procedures is defined in the Schedule 1 - Dictionary.
(11)      being treated with a drug which is associated in the individual with:
(a)          the development of anosmia within three weeks of commencing drug therapy, in the absence of clinical or laboratory evidence of anosmia prior to commencing drug therapy; and
(b)          the persistence of anosmia after discontinuing drug therapy;
(12)      undergoing a course of therapeutic radiation for cancer, where the olfactory neuroepithelium, olfactory bulb, or olfactory neural pathways in the brain were in the field of radiation, within the 30 days before the clinical onset of anosmia;
(13)      receiving an intranasal application of a preparation containing zinc gluconate or zinc sulphate within the 48 hours before the clinical onset of anosmia;
(14)      taking intranasal cocaine such that there is destruction of the nasal septum, palate or paranasal sinuses before the clinical onset of anosmia;
(15)      inhaling fumes from cadmium or nickel for a cumulative period of at least 5,000 hours before the clinical onset of anosmia and where that exposure has ceased, the clinical onset of anosmia has occurred within one year of cessation;
            Note: fumes is defined in the Schedule 1 - Dictionary.
(16)      inhaling fumes from acrylate or methylacrylate for a cumulative period of at least 5,000 hours before the clinical onset of anosmia and where that exposure has ceased,